Why the study?
The study evaluated the feasibility of in vivo real-time monitoring of anti-factor Xa levels using an integrated microdialysis-coupled microfluidic device to support development of bedside drug monitoring.
Key points are not available for this paper at this time.
Population
Rats
Comparison
Microdialysis-coupled microfluidic device vs conventional assay
Design
In vivo experimental animal study
Follow-up
7 hours
Supports preclinical development of real-time anti-Xa sensors; leaves open efficacy and safety in humans.
The feasibility of in vivo real-time monitoring of anti-factor Xa level had been explored using an integrated microdialysis-coupled microfluidic system. By customizing the dialysis membrane and utilizing a fluorogenic substrate, the performance of the integrated device was characterized and tested by continuous monitoring of the anti-factor Xa level in rats. Efficient sampling for low molecular weight heparin in the blood stream was demonstrated and the detection range of the device was determined to be 0.1-1.5 IU/ml. The anti-factor Xa profile was recorded for a period of 7 hours. Moreover, the results generated from this method agreed well with those from conventional assay. The present system provides a novel quantitative monitoring method with great precision, good reproducibility and full data coverage of treatment period. This study has paved the road for developing a bedside drug monitoring device in hospital setting.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: